Denmark · Delayed Price · Currency is DKK Embla Medical Statistics
Total Valuation
Embla Medical has a market cap or net worth of DKK 12.05 billion. The enterprise value is 14.94 billion.
| Market Cap | 12.05B |
| Enterprise Value | 14.94B |
Important Dates
The last earnings date was Tuesday, July 21, 2026.
| Earnings Date | Jul 21, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Embla Medical has 425.89 million shares outstanding. The number of shares has increased by 0.99% in one year.
| Current Share Class | 425.89M |
| Shares Outstanding | 425.89M |
| Shares Change (YoY) | +0.99% |
| Shares Change (QoQ) | +1.08% |
| Owned by Insiders (%) | 0.08% |
| Owned by Institutions (%) | 72.33% |
| Float | 156.55M |
Valuation Ratios
The trailing PE ratio is 19.75 and the forward PE ratio is 17.18. Embla Medical's PEG ratio is 1.05.
| PE Ratio | 19.75 |
| Forward PE | 17.18 |
| PS Ratio | 1.87 |
| PB Ratio | 1.99 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 14.63 |
| P/OCF Ratio | 12.88 |
| PEG Ratio | 1.05 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 11.86, with an EV/FCF ratio of 18.12.
| EV / Earnings | 24.29 |
| EV / Sales | 2.32 |
| EV / EBITDA | 11.86 |
| EV / EBIT | 16.52 |
| EV / FCF | 18.12 |
Financial Position
The company has a current ratio of 1.25, with a Debt / Equity ratio of 0.58.
| Current Ratio | 1.25 |
| Quick Ratio | 0.67 |
| Debt / Equity | 0.58 |
| Debt / EBITDA | 2.84 |
| Debt / FCF | 4.24 |
| Interest Coverage | 6.83 |
Financial Efficiency
Return on equity (ROE) is 10.71% and return on invested capital (ROIC) is 7.60%.
| Return on Equity (ROE) | 10.71% |
| Return on Assets (ROA) | 4.93% |
| Return on Invested Capital (ROIC) | 7.60% |
| Return on Capital Employed (ROCE) | 9.95% |
| Weighted Average Cost of Capital (WACC) | 5.86% |
| Revenue Per Employee | 1.43M |
| Profits Per Employee | 136,623 |
| Employee Count | 4,500 |
| Asset Turnover | 0.58 |
| Inventory Turnover | 2.33 |
Taxes
In the past 12 months, Embla Medical has paid 180.31 million in taxes.
| Income Tax | 180.31M |
| Effective Tax Rate | 22.61% |
Stock Price Statistics
The stock price has decreased by -12.11% in the last 52 weeks. The beta is 0.45, so Embla Medical's price volatility has been lower than the market average.
| Beta (5Y) | 0.45 |
| 52-Week Price Change | -12.11% |
| 50-Day Moving Average | 26.79 |
| 200-Day Moving Average | 29.98 |
| Relative Strength Index (RSI) | 66.59 |
| Average Volume (20 Days) | 144,023 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Embla Medical had revenue of DKK 6.44 billion and earned 614.80 million in profits. Earnings per share was 1.43.
| Revenue | 6.44B |
| Gross Profit | 4.01B |
| Operating Income | 875.62M |
| Pretax Income | 797.61M |
| Net Income | 614.80M |
| EBITDA | 1.03B |
| EBIT | 875.62M |
| Earnings Per Share (EPS) | 1.43 |
Balance Sheet
The company has 646.39 million in cash and 3.49 billion in debt, with a net cash position of -2.85 billion or -6.69 per share.
| Cash & Cash Equivalents | 646.39M |
| Total Debt | 3.49B |
| Net Cash | -2.85B |
| Net Cash Per Share | -6.69 |
| Equity (Book Value) | 6.06B |
| Book Value Per Share | 14.15 |
| Working Capital | 615.81M |
Cash Flow
In the last 12 months, operating cash flow was 935.43 million and capital expenditures -111.34 million, giving a free cash flow of 824.09 million.
| Operating Cash Flow | 935.43M |
| Capital Expenditures | -111.34M |
| Depreciation & Amortization | 157.96M |
| Net Borrowing | -374.82M |
| Free Cash Flow | 824.09M |
| FCF Per Share | 1.94 |
Margins
Gross margin is 62.31%, with operating and profit margins of 13.59% and 9.54%.
| Gross Margin | 62.31% |
| Operating Margin | 13.59% |
| Pretax Margin | 12.38% |
| Profit Margin | 9.54% |
| EBITDA Margin | 16.04% |
| EBIT Margin | 13.59% |
| FCF Margin | 12.75% |
Dividends & Yields
Embla Medical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.99% |
| Shareholder Yield | -0.99% |
| Earnings Yield | 5.10% |
| FCF Yield | 6.84% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Embla Medical is 33.50, which is 18.38% higher than the current price. The consensus rating is "Buy".
| Price Target | 33.50 |
| Price Target Difference | 18.38% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 8.63% |
| EPS Growth Forecast (3Y) | 18.30% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Embla Medical has an Altman Z-Score of 3.17 and a Piotroski F-Score of 6.
| Altman Z-Score | 3.17 |
| Piotroski F-Score | 6 |